← ANALYST RATINGS · TIPRANKS

Beta Bionics, Inc. (BBNX): analyst forecast and price target

$16.35 −5.55% close 16.10.26 · market cap $934M · General · Medical - Devices IWM 0.02%
Price targets and ratings of

Analyst consensus

Moderate Buy

10 Buy4 Hold0 Sell

Ratings of 14 analysts in the last 3 months

12-month forecast

$24.57+50.3% upside

Based on 14 price targets given in the last 3 months, the average target is $24.57, the highest $30.40, the lowest $16.00. The average is +50.3% from the last price of $16.35.

$10.00$20.00$30.00Jan 26AprJulOctJan 27AprJulOctHigh$30.40Average$24.57Low$16.00
Highest target $30.40 Average target $24.57 Lowest target $16.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Michael Toomey★★★★★★★★★★#10023 · hits 29% · avg −6.8% Jefferies $30.00 Buy +83.5% Initiated 12.10.26on TipRanks 05:45 +1.4%next day −0.9%
Christopher Pasquale★★★★★★★★★★#1776 · hits 61% · avg +11.9% Nephron $30.00 Buy +83.5% Initiated 06.10.26on TipRanks Oct 7 05:20 −2.2%next day −2.7% · 5 days −4.9%
Richard Newitter★★★★★★★★★★#1772 · hits 48% · avg +6.6% Truist Financial $23.00 → $28.00+21.7% Buy +71.3% Assigned 24.09.26on TipRanks 07:30 −1.9%next day −1.7% · 5 days −12.9%
Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% Wells Fargo $28.00 Buy +71.3% Initiated 23.09.26on TipRanks 05:10 −2.0%next day −1.9% · 5 days −13.8%
Frank Takkinen★★★★★★★★★★#11823 · hits 38% · avg −3.6% Lake Street $25.00 Buy +52.9% Reiterated 22.09.26on TipRanks 09:10 +3.5%next day −2.0% · 5 days −13.7%
Mike Kratky★★★★★★★★★★#1691 · hits 46% · avg +12.9% Leerink Partners $27.00 Buy +65.1% Reiterated 17.09.26on TipRanks Sep 14 08:45 +1.4%next day +15.4% · 5 days +29.8%
Jonathan Block★★★★★★★★★★#2320 · hits 50% · avg +5.3% Stifel Nicolaus $20.00 → $22.00+10.0% Buy +34.6% Reiterated 15.09.26on TipRanks 22:05 +15.8%next day −4.5% · 5 days −2.0%
Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% Robert W. Baird $14.00 → $16.00+14.3% Hold −2.1% Reiterated 15.09.26on TipRanks 07:05 +15.4%next day +15.8% · 5 days +16.3%
Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% UBS $22.00 → $25.00+13.6% Buy +52.9% Reiterated 15.09.26on TipRanks 06:45 +15.4%next day +15.8% · 5 days +16.3%
Travis Steed★★★★★★★★★★#3596 · hits 53% · avg +3.0% Bank of America Securities $18.00 → $20.00+11.1% Hold +22.3% Reiterated 14.09.26on TipRanks Sep 15 06:10 +1.4%next day +15.4% · 5 days +29.8%
Mathew Blackman★★★★★★★★★★#2177 · hits 49% · avg +9.2% TD Cowen $16.00 → $18.00+12.5% Hold +10.1% Reiterated 14.09.26on TipRanks 12:10 +1.4%next day +15.4% · 5 days +29.8%
Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% William Blair — Hold — Reiterated 14.09.26on TipRanks 11:35 +1.4%next day +15.4% · 5 days +29.8%
Jeffrey Cohen★★★★★★★★★★#11115 · hits 35% · avg −2.9% Ladenburg Thalmann & Co. $30.40 Buy +85.9% Reiterated 30.07.26on TipRanks 09:30 −7.6%next day −10.8% · 5 days −4.7%
Matthew O'Brien★★★★★★★★★★#12031 · hits 41% · avg −4.5% Piper Sandler $20.00 Buy +22.3% Reiterated 30.07.26on TipRanks 06:57 −7.6%next day −10.8% · 5 days −4.7%
David Roman★★★★★★★★★★#3715 · hits 53% · avg +5.3% Goldman Sachs $17.00 → $19.00+11.8% Buy +16.2% Assigned 15.07.26on TipRanks 06:30 −0.4%next day +0.8% · 5 days −2.3%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Beta Bionics, Inc.

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%
1 year David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%
2 years Matthew O'Brien★★★★★★★★★★Piper Sandler · #12031
Hits 41%201 of 490 Average return −4.5%

Most profitable

3 months David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%
1 year David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%
2 years David Roman★★★★★★★★★★Goldman Sachs · #3715
Hits 53%64 of 120 Average return +5.3%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $23.20 at a price of $18.98 (+22.2%); now: $24.57 at $16.35 (+50.3%).

$17.50$20.00$22.50$25.00Sep 15Oct 1Oct 15Top analysts$23.62Average target$24.57Price$16.35

PriceAverage targetTop analysts’ target

Recommendation trend

010201101Oct 251101Nov92Dec443Jan 261257Feb1346Mar1335Apr743May663Jun4103Jul283Aug2147Sep286Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy764222
Buy46108148
Hold333376
Sell000000

Earnings and sales forecast

Next report: 27.10.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.52 (from $-0.59 to $-0.42). Last quarter: $-0.53.

Sales

Next quarter’s sales estimate — $35M (from $34M to $36M). Last quarter: $32M.

Best top-analyst consensus in the sector · General

STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
About Beta Bionics, Inc.

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

Data from the stock’s TipRanks forecast page, read 26 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗